# Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

> **NCT06732258** · PHASE1 · WITHDRAWN · sponsor: **Sichuan University**

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **RADIATION:** Low-dose radiotherapy
- **DRUG:** Tifcemalimab injection
- **DRUG:** Toripalimab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT06732258
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01-10
- **Primary completion:** 2026-02-28
- **Final completion:** 2028-02-29
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Inorder to avoid the serious adverse effect of Toripalimab combining with Tifcemalimab, considering as the protection of participants.
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06732258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06732258, "Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06732258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*